000293335 001__ 293335
000293335 005__ 20250512134904.0
000293335 0247_ $$2doi$$a10.1007/s10654-024-01146-0
000293335 0247_ $$2pmid$$apmid:39294524
000293335 0247_ $$2ISSN$$a0393-2990
000293335 0247_ $$2ISSN$$a1573-7284
000293335 0247_ $$2altmetric$$aaltmetric:168147926
000293335 037__ $$aDKFZ-2024-01883
000293335 041__ $$aEnglish
000293335 082__ $$a610
000293335 1001_ $$0P:(DE-He78)a15e13b5e2dfc276ddddbf7505023951$$aSafizadeh, Fatemeh$$b0$$eFirst author$$udkfz
000293335 245__ $$aReevaluating the fraction of cancer attributable to excess weight: overcoming the hidden impact of prediagnostic weight loss.
000293335 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2024
000293335 3367_ $$2DRIVER$$aarticle
000293335 3367_ $$2DataCite$$aOutput Types/Journal article
000293335 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1728982167_16261
000293335 3367_ $$2BibTeX$$aARTICLE
000293335 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293335 3367_ $$00$$2EndNote$$aJournal Article
000293335 500__ $$a#EA:C070#LA:C070#LA:C120# / 2024 Sep;39(9):991-1003
000293335 520__ $$aTo evaluate the magnitude of the potential underestimation of the proportion of cancer cases attributable to excess weight, known as population attributable fraction (PAF), due to potential bias from prediagnostic weight loss already present at baseline of cohort studies and to overcome it as much as possible.Data from the UK Biobank cohort participants aged 40-69 without prior cancer diagnosis were analyzed. We assessed the magnitude of associations of excess weight with the incidence of obesity-related cancers combined, and separately for gastrointestinal (GI) and other cancers. Using multivariable Cox proportional hazards models, hazard ratios (HR) and their 95% confidence intervals (CI), and PAFs for excess weight at baseline were estimated for various periods of time after weight measurements.Of 458,660 participants, 20,218 individuals developed obesity-related cancers during a median 11.0-year follow-up, comprising 8,460 GI, and 11,765 non-GI cancers. PAFs were much higher for cancers occurring more than four years after recruitment than for cancers occurring within the initial four years: 17.7% versus 7.2%, 21.4% versus 11.7% for GI, non-GI and all obesity-related cancers combined, respectively. With respect to total cancer (including cancers with no established relationship with excess weight), PAFs were estimated as 5.1% and 8.8% for the 0-4 and 4-14-year periods of follow-up.The proportion of cancers attributable to excess weight is likely substantially larger than previously estimated based on cohort studies with short follow-up time or no or only limited exclusion of the early years of follow-up from the analyses.
000293335 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293335 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293335 650_7 $$2Other$$aBody mass index
000293335 650_7 $$2Other$$aCancer
000293335 650_7 $$2Other$$aObesity
000293335 650_7 $$2Other$$aOverweight
000293335 650_7 $$2Other$$aPopulation attributable fraction
000293335 7001_ $$0P:(DE-He78)6c325c717056d7ccd38066629f7dff6b$$aMandic, Marko$$b1$$udkfz
000293335 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b2$$udkfz
000293335 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000293335 773__ $$0PERI:(DE-600)2004992-4$$a10.1007/s10654-024-01146-0$$n9$$p991-1003$$tEuropean journal of epidemiology$$v39$$x0393-2990$$y2024
000293335 8564_ $$uhttps://inrepo02.dkfz.de/record/293335/files/s10654-024-01146-0.pdf
000293335 8564_ $$uhttps://inrepo02.dkfz.de/record/293335/files/s10654-024-01146-0.pdf?subformat=pdfa$$xpdfa
000293335 909CO $$ooai:inrepo02.dkfz.de:293335$$pVDB
000293335 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a15e13b5e2dfc276ddddbf7505023951$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000293335 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c325c717056d7ccd38066629f7dff6b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000293335 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000293335 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000293335 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293335 9141_ $$y2024
000293335 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-25$$wger
000293335 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-25$$wger
000293335 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-25$$wger
000293335 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J EPIDEMIOL : 2022$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000293335 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEUR J EPIDEMIOL : 2022$$d2023-08-25
000293335 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000293335 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000293335 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000293335 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000293335 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000293335 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000293335 980__ $$ajournal
000293335 980__ $$aVDB
000293335 980__ $$aI:(DE-He78)C070-20160331
000293335 980__ $$aI:(DE-He78)C120-20160331
000293335 980__ $$aI:(DE-He78)HD01-20160331
000293335 980__ $$aUNRESTRICTED